Evaluation of the inhibitory effect of 2,5-Dimethyl-Celecoxib on tamoxifen-sensitive and -resistant human breast cancer cells (MCF-7)
Clinical Medicine and Pharmacology · 2026
DOI: 10.70731/sh45n436 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Medicine and Pharmacology, 2026. Verfasst von Yingfen Wang und 5 weiteren Autor:innen. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Acquired endocrine-resistance has become a big clinical challenge in breast cancer endocrine therapy.We previously reported that simvastatin inhibited TamR cell growth by reducing the expression of minichromosome maintenance protein 7 (MCM7) and retinoblastoma protein (Rb), which caused a significant up-regulation of γH2AX expression and subsequently induces DNA damage.Our previous studies have demonstrated that 2,5-dimethyl-celecoxib (DMC) can significantly reduce MCM7 and Rb protein expression in both MCF-7 and MCF-7/TamR cell lines. Aimed to investigate the effect of DMC on the proliferation of TAM-sensitive and -resistant breast cancer cell lines as well as to evaluate the possible underlying inhibitory mechanism, MTT and apoptosis analysis were performed to detect cell proliferation and apoptosis.Western blotting assays were performed to analyse the protein expression levels of cell cycle and apoptosis regulators. Furthermore, immunofluorescence and comet assays were carried out to explore the mechanism of DNA damage.Finally, in vivo experiments are performed to verify the results of in vitro experiments. The results demonstrated that DMC inhibited the proliferation and increased the apoptosis of both TAM-sensitive and -resistant breast cancer cells in vitro. In addition, DMC was observed to down-regulate Rb/MCM7 and induce DNA damage, particularly when used in combination with TAM. Notably,DMC also proved to have the same effect in vivo model. In summary , the growth inhibition generated by DMC may be achieved by inhibiting the protein expression of Rb/MCM7 and subsequently inducing DNA damage. This study provides a novel strategy for the treatment of TamR breast cancer patients in the clinical setting.
Zitieren
APA
Wang, Y., Li, C., Li, A., Liu, P., Yan, X., & Tan, T. (2026). Evaluation of the inhibitory effect of 2,5-Dimethyl-Celecoxib on tamoxifen-sensitive and -resistant human breast cancer cells (MCF-7). Clinical Medicine and Pharmacology. https://doi.org/10.70731/sh45n436
Vancouver
Wang Y, Li C, Li A, Liu P, Yan X, Tan T. Evaluation of the inhibitory effect of 2,5-Dimethyl-Celecoxib on tamoxifen-sensitive and -resistant human breast cancer cells (MCF-7). Clinical Medicine and Pharmacology. 2026. doi:10.70731/sh45n436
BibTeX
@article{Wang2026,
author = {Wang, Yingfen and Li, Chao and Li, Aoying and Liu, Peijun and Yan, Xuemei and Tan, Tan},
title = {Evaluation of the inhibitory effect of 2,5-Dimethyl-Celecoxib on tamoxifen-sensitive and -resistant human breast cancer cells (MCF-7)},
journal = {Clinical Medicine and Pharmacology},
year = {2026},
doi = {10.70731/sh45n436}
}
EUVIMED